WEEKLY CARFILZOMIB WITH DEXAMETHASONE FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS FROM THE PHASE 1/2 STUDY CHAMPION-1 (NCT01677858)

被引：0

作者：

Berenson, J. ^{[1
]}

Cartmell, A. ^{[2
]}

Lyons, R. ^{[3
,4
]}

Harb, W. ^{[5
]}

Tzachanis, D. ^{[6
]}

Agajanian, R. ^{[7
]}

Boccia, R. ^{[8
]}

Coleman, M. ^{[9
]}

Moss, R. A. ^{[10
]}

Rifkin, R. M. ^{[11
,12
]}

Schupp, M. ^{[13
]}

Dixon, S. ^{[13
]}

Ou, Y. ^{[13
]}

Anderl, J. ^{[13
]}

Berdeja, J. ^{[14
]}

机构：

[1] Inst Myeloma & Bone Canc Res, Los Angeles, CA USA

[2] Comprehens Blood & Canc Ctr, Bakersfield, CA USA

[3] US Oncol Res Ctr South Texas, San Antonio, TX USA

[4] US Canc Care Ctr South Texas, San Antonio, TX USA

[5] Horizon Oncol Ctr, Lafayette, IN USA

[6] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA

[7] Oncol Inst Hope & Innovat, Downey, CA USA

[8] Ctr Canc & Blood Disorders, Bethesda, MD USA

[9] NewYork Presbyterian Weill Cornell, New York, NY USA

[10] Robert A Moss MD Inc, Fountain Valley, CA USA

[11] US Oncol Res Canc Ctr, Denver, CO USA

[12] US Rocky Mt Canc Ctr, Denver, CO USA

[13] Amgen Inc, Thousand Oaks, CA USA

[14] Sarah Cannon Res Inst, Nashville, TN USA

来源：

HAEMATOLOGICA | 2016年 / 101卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P661

引用

页码：261 / 262

页数：2

共 50 条

[21] Weekly carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed or refractory multiple myeloma (RRMM): A phase 1b study.
Biran, Noa
Siegel, David Samuel DiCapua
Berdeja, Jesus G.
Raje, Noopur S.
Cornell, Robert F.
Alsina, Melissa
Kovacsovics, Tibor
Fang, Belle
Kimball, Amy
Landgren, Carl Ola
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[22] Initial Phase 2 Results of Ibrutinib Combined with Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Chari, Ajai
Girnius, Saulius
Chhabra, Saurabh
Cornell, Robert Frank
Gasparetto, Cristina J.
Karanes, Chatchada
Lunning, Matthew A.
Matous, Jeffrey V.
Niesvizky, Ruben
Shustik, Chaim
Stuart, Robert K.
Lih, Jason
Lee, Yihua
Salman, Zeena
Graef, Thorsten
Valent, Jason
BLOOD, 2017, 130
[23] Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
Thomas Martin
Meletios-Athanasios Dimopoulos
Joseph Mikhael
Kwee Yong
Marcelo Capra
Thierry Facon
Roman Hajek
Ivan Špička
Ross Baker
Kihyun Kim
Gracia Martinez
Chang-Ki Min
Ludek Pour
Xavier Leleu
Albert Oriol
Youngil Koh
Kenshi Suzuki
France Casca
Sandrine Macé
Marie-Laure Risse
Philippe Moreau
Blood Cancer Journal, 13
[24] A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
Yee, Andrew J.
Nadeem, Omar
Rosenblatt, Jacalyn
Bianchi, Giada
O'Donnell, Elizabeth
Branagan, Andrew R.
Harrington, Cynthia C.
Agyemang, Emerentia A.
Gammon, Marilyn T.
Lively, Kathleen J.
Packer, Lisette A.
Bernstein, Zachary S.
Lyons, Rebecca T.
Riadi, Manal
Rowell, Sean M.
Mcvey, Cailin
Goguen, Amy C.
Horick, Nora K.
Richardson, Paul G.
Raje, Noopur S.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[25] Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study
Iida, Shinsuke
Watanabe, Takashi
Matsumoto, Morio
Suzuki, Kenshi
Sunami, Kazutaka
Ishida, Tadao
Ando, Kiyoshi
Chou, Takaaki
Ozaki, Shuji
Taniwaki, Masafumi
Uike, Naokuni
Shibayama, Hirohiko
Hatake, Kiyohiko
Izutsu, Koji
Ishikawa, Takayuki
Shumiya, Yoshihisa
Tobinai, Kensei
CANCER SCIENCE, 2019, 110 (09) : 2924 - 2932
[26] A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China
Juan Du
Baijun Fang
Jian Li
Jie Jin
Shunqing Wang
Dehui Zou
Zhen Cai
Hongxiang Wang
Jianda Hu
Wei Li
Chengcheng Fu
Zonghong Shao
Zhongjun Xia
Peng Liu
Ting Niu
En-Tzu Tang
Amy S. Kimball
Jian Hou
Wenming Chen
International Journal of Hematology, 2021, 113 : 422 - 429
[27] Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)
Plesner, Torben
Arkenau, Hendrik-Tobias
Gimsing, Peter
Krejcik, Jakub
Lemech, Charlotte
Minnema, Monique C.
Lassen, Ulrik
Laubach, Jacob P.
Palumbo, Antonio
Lisby, Steen
Basse, Linda
Wang, Jianping
Sasser, A. Kate
Guckert, Mary E.
Yeh, Howard
Ahmadi, Tahamtan
Lokhorst, Henk M.
Richardson, Paul G.
BLOOD, 2015, 126 (23)
[28] A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China
Du, Juan
Fang, Baijun
Li, Jian
Jin, Jie
Wang, Shunqing
Zou, Dehui
Cai, Zhen
Wang, Hongxiang
Hu, Jianda
Li, Wei
Fu, Chengcheng
Shao, Zonghong
Xia, Zhongjun
Liu, Peng
Niu, Ting
Tang, En-Tzu
Kimball, Amy S.
Hou, Jian
Chen, Wenming
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (03) : 422 - 429
[29] CARFILZOMIB AND DEXAMETHASONE VS BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: RESULTS OF THE PHASE 3 STUDY ENDEAVOR (NCT01568866)
Rocafiguera Albert, Oriol
Laura, Rosinol
Hartmut, Goldschmidt
Philippe, Moreau
Antonio, Palumbo
Douglas, Joshua
Ludek, Pour
Roman, Hajek
Thierry, Facon
Heinz, Ludwig
Ruben, Niesvizky
Jan, Straub
Aleksandr, Suvorov
Carla, Araujo
Elena, Rimashevskaya
Tomas, Pika
Gianluca, Gaidano
Katja, Weisel
Vesselina, Goranova-Marinova
Anthony, Schwarer
Leonard, Minuk
Karim, Iskander
Shibao, Feng
Sanjay, Aggarwal
Meletios A, Dimopoulos
HAEMATOLOGICA, 2016, 101 : 28 - 29
[30] Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
Costa, Luciano J.
Stadtmauer, Edward Allen
Morgan, Gareth John
Monohan, Gregory P.
Kovacsovics, Tibor
Burwick, Nicholas
Jakubowiak, Andrzej J.
Mobasher, Mehrdad
Freise, Kevin
Ross, Jeremy A.
Pesko, John Carl
Munasinghe, Wijith
Cordero, Jaclyn
Morris, Lura
Maciag, Paulo Cesar
Bueno, Orlando
Kumar, Shaji
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 5 →